Ergomed plc Share Capital Reduction Effective (6446F)
18 November 2020 - 6:00PM
UK Regulatory
TIDMERGO
RNS Number : 6446F
Ergomed plc
18 November 2020
PRESS RELEASE
Share Capital Reduction Effective
Guildford, UK - 18 November 2020 : Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, announces
that, further to its announcements on 1 October and 19 October
2020, the High Court of England and Wales sanctioned on 10 November
2020 the Company's application for its Capital Reduction.
On 17 November 2020 the Registrar of Companies registered the
order of the High Court confirming the Capital Reduction and the
related statement of capital approved by the High Court, whereupon
the Capital Reduction became effective.
The Company confirms that, following the Capital Reduction, the
issued share capital of the Company comprises 48,717,776 ordinary
shares of 1p each and there are no shares held in treasury. The
total number of voting rights in the Company is therefore
48,717,776.
Terms used but not defined in this announcement are as defined
in the Company's announcement of 1 October 2020.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated
Adviser)
James Black (Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Sue Stuart ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services business includes an industry leading suite of
specialist pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality contract
research and trial management services under the Ergomed brand
(CRO), and an internationally recognised specialist expertise in
orphan drug development, under PSR. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRVDLFFBFLFFBE
(END) Dow Jones Newswires
November 18, 2020 02:00 ET (07:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024